Monoclonal antibody · Antagonist of misfolded light chain aggregates and amyloid fibrils · developed by Prothena Biosciences
Birtamimab (NEOD001) is a humanized IgG1 monoclonal antibody that binds misfolded light chain aggregates and amyloid fibrils. It is studied in patients with light chain (AL) amyloidosis, where it aims to prevent amyloid deposit formation and promote their clearance from organs.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04973137 | Phase 3 | Light Chain (AL) Amyloidosis | Terminated | PRTA |
| NCT02312206 | Phase 3 | Primary Systemic (AL) Amyloidosis | Terminated | PRTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Light Chain (AL) AmyloidosisPrimary Systemic (AL) Amyloidosis
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRTA page.
See PRTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRTA catalysts and pipeline →